Compare Cassava Sciences Inc (FLNA) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.21 (market cap $4.35B). The key difference: State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF is far larger — about 110.4× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 3,211,044). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 41 Days on average.
| FLNA | SJNK | |
|---|---|---|
Market Cap | $39.40M | $4.35B |
Volume | 759,018 | 3,211,044 |
Sector | Health | Fixed Income |
52-Week High | $4.64 | $25.57 |
52-Week Low | $0.68 | $24.13 |
Typical Hold Time | 37 Days | 41 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
SJNK, the SPDR Bloomberg Short Term High Yield Bond ETF, trades at $24.18 with a slight 24-hour decline of 0.08%. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF has maintained consistent dividend payments recently, with three distributions of $0.14-$0.15 scheduled for late 2026. Institutional activity shows mixed sentiment with Cetera Investment Advisers and Balefire LLC reducing positions in recent quarters.
The ETF faces headwinds from the current bearish technical setup while offering yield advantages over Treasury securities. Key risks include interest rate sensitivity and high-yield bond market volatility. Investors should weigh the attractive dividend yield against the technical weakness and institutional selling pressure when considering position sizing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
